In the following subparagraphs, we reviewed the pro-tumor activity of AIM2, focusing on the recent findings about the involvement of the AIM2 receptor in the establishment and progression of ovarian and prostate cancer, oral malignancies, pancreatic and lung cancer (Figure 2). Here, AIM2 is linked to prostate carcinoma.